C4 Therapeutics, Inc.
CCCC
$4.24
$0.163.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.04M | 34.86M | 35.95M | 30.11M | 34.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.04M | 34.86M | 35.95M | 30.11M | 34.24M |
| Cost of Revenue | 4.79M | 6.51M | 8.98M | 13.67M | 19.52M |
| Gross Profit | 30.25M | 28.35M | 26.97M | 16.44M | 14.72M |
| SG&A Expenses | 36.02M | 36.20M | 36.20M | 37.39M | 40.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.07M | 137.97M | 140.44M | 149.16M | 157.86M |
| Operating Income | -101.03M | -103.11M | -104.49M | -119.05M | -123.62M |
| Income Before Tax | -101.30M | -103.68M | -104.87M | -118.95M | -111.45M |
| Income Tax Expenses | 121.00K | 121.00K | 121.00K | 131.00K | 131.00K |
| Earnings from Continuing Operations | -101.42 | -103.80 | -104.99 | -119.08 | -111.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.42M | -103.80M | -104.99M | -119.08M | -111.58M |
| EBIT | -101.03M | -103.11M | -104.49M | -119.05M | -123.62M |
| EBITDA | -99.45M | -101.20M | -102.53M | -117.04M | -121.63M |
| EPS Basic | -1.00 | -1.18 | -1.36 | -1.67 | -1.58 |
| Normalized Basic EPS | -0.54 | -0.66 | -0.77 | -0.97 | -1.00 |
| EPS Diluted | -1.00 | -1.18 | -1.36 | -1.67 | -1.58 |
| Normalized Diluted EPS | -0.54 | -0.66 | -0.77 | -0.97 | -1.00 |
| Average Basic Shares Outstanding | 446.12M | 386.43M | 331.19M | 285.01M | 282.07M |
| Average Diluted Shares Outstanding | 446.12M | 386.43M | 331.19M | 285.01M | 282.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |